FK506 and pregnancy in liver transplant patients by Jain, A et al.
September 1993 BRIEF COMMUNICATIONS 
fusion index in the management of renal transplants. J Nucl 
Med 1978; 19: 994. 
8. Kerman RH, Floyd M, Conner W, et al. Combined immunologic 
and radionuc1eide techniques to monitor renal allograft rejection. 
Transplant Proc 1979; 11: 1229. 
9. Kim EE, Pjura G, Lowry P, et al. CyclosPorin-A nephrotoxicity 
and acute cellular rejection in renal transplant recipients: corre-
lation between radionucleide and histologic fmdings. Radiology 
1986; 159: 443. 
10. Gedroyc W, Taube D, Fogleman I, Neild G, Cameron S, Maisey 
M. Tc-99M-DTPA scans in renal allograft rejection and cyclo-
sporine nephrotoxicity. Transplantation 1986; 42: 494. 
11. Pjura.GA, Kim EE, Lowry PA, Verani RR, Kahan BD, Crews LD. 
Radionucleide differentiation of acute cellular rejection from 
cycloaporine nephrotoxicity. Contr Nephro11987; 56: 163. 
Received 26 August 1992. 
Accepted 11 December 1992. 
FK506 AND PREGNANCY IN LIVER TRANSPLANT PATIENTS 1ljJ2 
There have been several reports of successful pregnancy in 
organ transplant patients treated with AZA, steroids, or CsA 
(1,2). However, the use of these immunosuppressive drugs in 
renal transplant patients is often associated with preeclampsia, 
preterm births, and severe intrauterine growth retardation (1). 
Earlier, we have reported pregnancy in liver transplant patients 
treated with AZA or CsA at the University of Pittsburgh 
Medical Center (3). In the present communication, we sum-
marize our recent experience with pregnancy in liver transplant 
patients treated with FK506 as the primary immunosuppressive 
drug. 
At the present time, there are 876 males and 627 female liver 
transplant patients on FK506 immunosuppression at the Uni-
versity of Pittsburgh Medical Center. Nine pregnancies have 
been recorded in 9 of these patients on FK506 therapy. These 
patients received liver transplantation for Caroli's disease (1), 
primary biliary cirrhosis (1), alcoholic cirrhosis (2), cryptogenic 
cirrhosis (2), fulminant hepatic failure (1), autoimmune hepa-
titis (1), or non-A non-B hepatitis (1). The age of the mothers 
ranged from 18 to 35 years. Four of them were primary FK506 
patients and 5 of them were switched to FK506 therapy after 
chronic rejection while on CsA. All of the patients received 
FK506 with (n=5) or without steroid (n=4) therapy during the 
entire period of pregnancy. The FK506 doses ranged from 2 mg 
qd to 32 mg bid. Two patients had mild hypertension and 1 
had proteinurea during pregnancy. Six of the 9 patients had 
normal vaginal delivery; 3 patients required cesarean section 
for previous classical cesarean section, placenta abruptio, or 
antepartum hemorrhage. All the patients had normal liver 
function before pregnancy, and 2 patients who experienced an 
episode of rejection during pregnancy were treated successfully 
with high-dose steroids. Table 1 lists the clinical data on the 
patients and the infants born. None of the babies was consid-
ered small for gestational age, based on the Colorado intrauter-
ine Growth Charts (4). 
Five of the 7 babies for whom potassium levels were available 
had hyperkalemia (range 6.1-10.9 mEqfL) at the time of birth 
that resolved spontaneously within 24-48 hr without any treat-
ment. One baby who was delivered by a patient known to be a 
cocaine addict was hypoxic, tested positive for cocaine, re-
mained in the incubator for 2 weeks, but recovered after that 
time period. One baby who was born to a mother with renal 
impairment during pregnancy was anuric for 36 hr, secondary 
to high FK506 concentrations in the cord, but regained normal 
renal function in 1 week. The only baby that died 2 hr after 
birth was born prematurely (22 weeks) to a 20-year-old patient 
who conceived within a month after transplantation. This 
patient had evidence of CMV in the blood and gastrointestinal 
tract and was treated with ganciclovir. Eight of the 9 babies 
are currently alive and are developing normally. In conclusion, 
liver transplant patients on FK506 appear to have a normal 
course of pregnancy and, in the majority of cases, give birth to 
normal and healthy babies. 
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SUCCESSFUL PREGNANCY IN A PATIENT AFTER LIVER TRANSPLANTATION MAINTAINED ON FK 506 
FK 506 is a novel macrolide immunosuppressant that is 
currently under clinical investigation in patients after solid 
organ transplantation. We here report on a successful preg-
nancy in a patient treated with FK 506. To our knowledge, this 
is the first report of a patient under FK 506 immunosuppression 
who gave birth to a healthy child. 
Case report. A 28-year-old woman was liver grafted for post-
hepatic cirrhosis. After the loss of the f1l'8t graft due to intrac-
table chronic rejection, the second graft again showed signs of 
chronic rejection (Fig. 1). Therefore, FK 506 treatment (0.10 
